Summary

The anatomic pathology market is projected to grow from USD 8.9 billion in 2026 to USD 14.5 billion by 2031, at a CAGR of 10.2%. The increasing global prevalence of cancer and other chronic diseases is driving demand for histopathology, cytopathology, and biomarker-based diagnostic testing. As healthcare systems increasingly adopt personalized medicine approaches, the need for accurate tissue characterization and biomarker assessment is expanding across a wide range of cancer types. Furthermore, advancements in digital pathology, artificial intelligence, laboratory automation, and multiplex tissue analysis technologies are improving diagnostic efficiency, workflow standardization, and clinical decision-making. These innovations are enabling healthcare providers to deliver more accurate and timely diagnoses, thereby supporting the growth of the anatomic pathology market. The breast cancer segment is expected to account for the largest share of the anatomic pathology market, by disease type. Based on disease type, the anatomic pathology market is segmented into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer (NSCLC), and other diseases. The breast cancer segment accounts for the largest market share due to the high global incidence of the disease and the extensive use of anatomic pathology techniques for disease diagnosis, classification, grading, and treatment planning. Pathology laboratories routinely utilize histopathology, immunohistochemistry (IHC), in situ hybridization (ISH), and biomarker assessment to support comprehensive evaluation of breast tissue specimens. Additionally, the increasing emphasis on early cancer detection, growing breast cancer screening initiatives, and rising demand for accurate pathological characterization continue to drive the adoption of anatomic pathology solutions, making breast cancer the largest disease segment within the market. The hospitals segment is expected to account for the largest share of the anatomic pathology market. The global anatomic pathology market can be segmented by end user into hospitals, research laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. Among these, the hospitals segment accounted for the largest market share. Hospitals remain the primary setting for anatomic pathology testing due to the high volume of cancer diagnoses, surgical procedures, and tissue-based examinations performed within integrated healthcare systems. Furthermore, the increasing availability of advanced pathology infrastructure, growing adoption of laboratory automation and digital pathology technologies, and rising demand for timely and accurate diagnostic services are expected to support the continued utilization of anatomic pathology solutions across hospital-based laboratories worldwide. The Asia Pacific is the fastest-growing market for anatomic pathology from 2026 to 2031. The global anatomic pathology market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. The region is witnessing a rapid increase in cancer incidence, creating significant demand for histopathology, cytopathology, and biomarker-based diagnostic services. China is expanding pathology laboratory capacity through healthcare infrastructure modernization initiatives and increasing investments in cancer diagnostics. India's growing network of tertiary-care hospitals, cancer centers, and private diagnostic laboratories is accelerating the adoption of advanced pathology technologies and laboratory automation. Meanwhile, Japan's aging population, high cancer screening rates, and increasing adoption of digital pathology solutions continue to support the expansion of the anatomic pathology market across the region. The break-up of the profiles of primary participants in the anatomic pathology market: • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) • By Designation: C-level Executives (27%), Directors (18%), and Others (55%) • By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Hologic, Inc. (US), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (US), Koninklijke Philips N.V. (Netherlands), Merck KGaA (Germany), Bio SB (US), and Sakura Finetek Japan Co., Ltd. (Japan) are some of the key players in the anatomic pathology market. Research Coverage: This research report categorizes the anatomic pathology market into the product market by type (consumables, instruments, software, and storage systems), product market by process (preanalytics/sample preparation, advanced staining/IHC, primary & special staining, and digital pathology), product market by disease (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer, and other diseases), product market by end user (hospitals, research laboratories, pharmaceutical companies, contract research organizations, and other end users), service market by type (histopathology services and cytopathology services), service market by model (in-house and outsourced), service market by disease (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer, and other diseases, and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the anatomic pathology market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions; key strategies such as acquisitions, agreements, and product & service launches; and recent developments associated with the anatomic pathology market. Competitive analysis of upcoming startups in the anatomic pathology market ecosystem is covered in this report. Reasons to buy this report: The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall anatomic pathology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (high incidence of cancer and other target diseases, growing demand for digital pathology, availability of reimbursement, and growing focus on personalized medicine), restraints (high cost of instruments and consumables), opportunities (expansion potential across emerging economies and increasing number of clinical trials for cancer therapeutics), and challenges (availability of refurbished products, stringent regulatory requirements, and shortage of skilled professionals) influencing the growth of the anatomic pathology market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the anatomic pathology market. • Market Development: Comprehensive information about lucrative markets—the report analyzes the anatomic pathology market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the anatomic pathology market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Hologic, Inc. (US), Agilent Technologies, Inc. (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.3 STUDY SCOPE 45
1.3.1 MARKETS COVERED & REGIONAL SCOPE 45
1.3.2 INCLUSIONS & EXCLUSIONS 46
1.3.3 YEARS CONSIDERED 47
1.4 CURRENCY CONSIDERED 47
1.5 STAKEHOLDERS 47
1.6 SUMMARY OF CHANGES 48
2 EXECUTIVE SUMMARY 49
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 49
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 50
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 51
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 52
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 53
3 PREMIUM INSIGHTS 54
3.1 ANATOMIC PATHOLOGY PRODUCT MARKET OVERVIEW 54
3.2 ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE, 2026 VS. 2031 54
3.3 ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS, 2026 VS. 2031 55
3.4 ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE, 2026 VS. 2031 55
3.5 ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER, 2026 VS. 2031 56
3.6 ANATOMIC PATHOLOGY PRODUCT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
4 MARKET OVERVIEW 57
4.1 INTRODUCTION 57
4.2 MARKET DYNAMICS 57
4.2.1 DRIVERS 58
4.2.1.1 High incidence of cancer and other target diseases 58
4.2.1.2 Growing demand for digital pathology 59
4.2.1.3 Availability of reimbursement 60
4.2.1.4 Growing focus on personalized medicine 61
4.2.2 RESTRAINTS 62
4.2.2.1 High cost of instruments and consumables 62
4.2.3 OPPORTUNITIES 62
4.2.3.1 Expansion potential across emerging economies 62
4.2.3.2 Increasing number of clinical trials for cancer therapeutics 63
4.2.4 CHALLENGES 63
4.2.4.1 Availability of refurbished products 63
4.2.4.2 Stringent regulatory requirements 63
4.2.4.3 Shortage of skilled professionals 64
4.3 UNMET NEEDS & WHITE SPACES 64
4.3.1 UNMET NEEDS IN ANATOMIC PATHOLOGY MARKET 64
4.3.2 WHITE SPACE OPPORTUNITIES 65
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 66
4.4.1 INTERCONNECTED MARKETS 66
4.4.2 CROSS-SECTOR OPPORTUNITIES 67
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 68
4.5.1 KEY MOVES & STRATEGIC FOCUS 68
5 INDUSTRY TRENDS 69
5.1 PORTER’S FIVE FORCES ANALYSIS 69
5.1.1 BARGAINING POWER OF SUPPLIERS 70
5.1.2 BARGAINING POWER OF BUYERS 70
5.1.3 THREAT OF NEW ENTRANTS 70
5.1.4 THREAT OF SUBSTITUTES 70
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.2 MACROECONOMIC INDICATORS 71
5.2.1 INTRODUCTION 71
5.2.2 GDP TRENDS & FORECAST 71
5.3 SUPPLY CHAIN ANALYSIS 74
5.4 VALUE CHAIN ANALYSIS 75
5.5 ECOSYSTEM ANALYSIS 76
5.5.1 ANATOMIC PATHOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 77
5.6 PRICING ANALYSIS 77
5.6.1 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS,
BY KEY PLAYER, 2024–2026 78
5.6.2 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS,
BY REGION, 2024–2026 79
5.7 TRADE ANALYSIS 80
5.7.1 IMPORT SCENARIO (HS CODE 3822) 80
5.7.2 EXPORT SCENARIO (HS CODE 3822) 81
5.8 KEY CONFERENCES & EVENTS, 2026–2027 81
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 82
5.10 INVESTMENT & FUNDING SCENARIO 83
5.11 CASE STUDY ANALYSIS 83
5.11.1 CASE STUDY 1: OPTIMIZING AUTOMATED TISSUE PROCESSING
EFFICIENCY TO REDUCE COST 83
5.11.2 CASE STUDY 2: OPERATIONAL EFFICIENCY IMPROVEMENTS THROUGH MILESTONE MEDICAL TISSUE PROCESSOR IMPLEMENTATION 84
5.11.3 CASE STUDY 3: WORKFLOW OPTIMIZATION THROUGH EXCELSIOR
AS TISSUE PROCESSOR 84
5.12 IMPACT OF 2025 US TARIFFS ON ANATOMIC PATHOLOGY MARKET 85
5.12.1 INTRODUCTION 85
5.12.2 KEY TARIFF RATES 85
5.12.3 PRICE IMPACT ANALYSIS 85
5.12.4 IMPACT ON REGION 86
5.12.4.1 North America 86
5.12.4.2 Europe 86
5.12.4.3 Asia Pacific 87
5.12.5 IMPACT ON END-USE INDUSTRIES 87
5.12.5.1 Hospitals 87
5.12.5.2 Research laboratories 87
5.12.5.3 Pharmaceutical companies 87
5.12.5.4 Contract research organizations (CROs) 88
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89
6.1 KEY EMERGING TECHNOLOGIES 89
6.1.1 HISTOPATHOLOGY 89
6.1.2 CYTOPATHOLOGY 89
6.1.3 DIGITAL PATHOLOGY 89
6.2 COMPLEMENTARY TECHNOLOGIES 90
6.2.1 SPECIAL STAINING 90
6.3 ADJACENT TECHNOLOGIES 90
6.3.1 MASS SPECTROMETRY IMAGING (MSI) 90
6.4 TECHNOLOGY/PRODUCT ROADMAP 90
6.4.1 SHORT-TERM (2025–2027) | OPTIMIZATION & STANDARDIZATION
OF CORE REAGENTS 91
6.4.1.1 Core technology development 91
6.4.1.2 Product innovations 91
6.4.1.3 Market adoption 91
6.4.2 MID-TERM (2027–2030) | EXPANDED CAPABILITIES & SUSTAINABILITY 91
6.4.2.1 Advanced technology development 91
6.4.2.2 Product innovations 91
6.4.2.3 Market adoption 92
6.4.3 LONG-TERM (2030–2035+) | HIGH-PERFORMANCE & ECO-EFFICIENT PRODUCTS 92
6.4.3.1 High-performance & integrated workflows 92
6.4.3.2 Product innovations 92
6.4.3.3 Market adoption 92
6.5 PATENT ANALYSIS 92
6.5.1 LIST OF MAJOR PATENTS 93
6.5.1.1 List of key patents 93
6.6 FUTURE APPLICATIONS 94
6.7 IMPACT OF AI/GENERATIVE AI ON ANATOMIC PATHOLOGY MARKET 95
6.7.1 INTRODUCTION 95
6.7.2 TOP USE CASES & MARKET POTENTIAL 95
6.7.3 KEY COMPANIES IMPLEMENTING AI 96
6.7.4 FUTURE OF AI 96
7 SUSTAINABILITY & REGULATORY LANDSCAPE 97
7.1 REGIONAL REGULATIONS & COMPLIANCE 97
7.1.1 REGULATORY ANALYSIS 97
7.1.1.1 North America 97
7.1.1.1.1 US 97
7.1.1.1.2 Canada 97
7.1.1.2 Europe 97
7.1.1.2.1 Germany 98
7.1.1.2.2 UK 98
7.1.1.2.3 France 99
7.1.1.3 Asia Pacific 99
7.1.1.3.1 China 99
7.1.1.3.2 Japan 99
7.1.1.3.3 India 100
7.1.1.4 Latin America 100
7.1.1.5 Middle East 100
7.1.1.5.1 Africa 101
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
7.2 SUSTAINABILITY INITIATIVES 103
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES
IN ANATOMIC PATHOLOGY MARKET 103
7.2.1.1 Eco-friendly initiatives 103
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 104
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 106
8.1 DECISION-MAKING PROCESS 106
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 106
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 106
8.2.2 BUYING CRITERIA 107
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 107
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 109
8.5 MARKET PROFITABILITY 110
8.5.1 REVENUE POTENTIAL 110
8.5.2 COST DYNAMICS 110
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 111
9 ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE 112
9.1 INTRODUCTION 113
9.2 CONSUMABLES 113
9.2.1 HISTOPATHOLOGY CONSUMABLES 114
9.2.1.1 Histopathology antibodies 116
9.2.1.1.1 Primary histopathology antibodies 118
9.2.1.1.1.1 Increasing adoption of precision medicine to drive market growth 118
9.2.1.1.2 Secondary histopathology antibodies 120
9.2.1.1.2.1 Growing focus on highly specific polymers to drive demand for histopathology secondary antibodies 120
9.2.1.2 Histopathology kits & reagents 122
9.2.1.2.1 Histopathology stains & solvents 124
9.2.1.2.1.1 Increasing adoption of advanced tissue staining techniques to drive growth of histopathology stains & solvents 124
9.2.1.2.2 Histopathology fixatives 125
9.2.1.2.2.1 Growing emphasis on tissue preservation and biomarker integrity to drive demand for histopathology fixation reagents 125
9.2.1.2.3 Other histopathology kits & reagents 127
9.2.1.3 Histopathology probes 129
9.2.1.3.1 Growing adoption of tissue-based pathology and precision diagnostics to drive demand for histopathology probes 129
9.2.1.4 Other histopathology consumables 131
9.2.2 CYTOPATHOLOGY CONSUMABLES 133
9.2.2.1 Cytopathology antibodies 135
9.2.2.1.1 Primary cytopathology antibodies 137
9.2.2.1.1.1 Advancements in biomarker research using cell analysis to support market growth 137
9.2.2.1.2 Secondary cytopathology antibodies 139
9.2.2.1.2.1 Expanding use of cytopathology for cancer screening to accelerate demand 139
9.2.2.2 Cytopathology kits & reagents 141
9.2.2.2.1 Cytopathology stains & solvents 143
9.2.2.2.1.1 Growing demand for cytology-based screening and cellular diagnostics to fuel cytopathology stains & solvents market 143
9.2.2.2.2 Cytopathology fixatives 144
9.2.2.2.2.1 Rising adoption of cytology-based screening and liquid-based cytology to support growth of cytopathology fixation reagents 144
9.2.2.2.3 Other cytopathology kits & reagents 146
9.2.2.3 Cytopathology probes 148
9.2.2.3.1 Increasing research to aid market growth 148
9.2.2.4 Other cytopathology consumables 150
9.3 INSTRUMENTS 151
9.3.1 SLIDE STAINING SYSTEMS 152
9.3.1.1 Availability of automated systems to drive market growth 152
9.3.2 TISSUE PROCESSING SYSTEMS 154
9.3.2.1 Rising adoption of automation to drive market growth 154
9.3.3 CELL PROCESSORS 157
9.3.3.1 Technological advancements in cytopathology testing to support growth of this market 157
9.3.4 MICROTOMES 158
9.3.4.1 Increasing demand for accurate tissue sectioning to support growth 158
9.3.5 EMBEDDING SYSTEMS 161
9.3.5.1 Advancements in tissue preparation technologies to support expansion of embedding systems market 161
9.3.6 COVERSLIPPERS 163
9.3.6.1 Increasing focus on laboratory automation and workflow efficiency to drive growth of coverslippers market 163
9.3.7 DIGITAL PATHOLOGY SCANNERS 164
9.3.7.1 Growing adoption of digital imaging to propel market 164
9.3.8 OTHER INSTRUMENTS 167
9.4 SOFTWARE 168
9.4.1 AI-INTEGRATED SOFTWARE 169
9.4.1.1 Growing adoption of artificial intelligence in pathology workflows to accelerate demand for AI-integrated software 169
9.4.2 NON-AI-INTEGRATED SOFTWARE 172
9.4.2.1 Increasing digitalization of pathology laboratories to drive demand for non-AI pathology software 172
9.5 STORAGE SYSTEMS 174
9.5.1 GROWING ADOPTION OF DIGITAL PATHOLOGY AND INCREASING DATA VOLUMES TO DRIVE DEMAND FOR PATHOLOGY STORAGE SYSTEMS 174
10 ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS 176
10.1 INTRODUCTION 177
10.2 PREANALYTICS/SAMPLE PREPARATION 177
10.2.1 GROWING DEMAND FOR EFFICIENT SPECIMEN HANDLING AND LABORATORY AUTOMATION TO DRIVE GROWTH 177
10.3 ADVANCED STAINING/IHC 179
10.3.1 GROWING ADOPTION OF MULTIPLEX BIOMARKER ANALYSIS AND AUTOMATED STAINING WORKFLOWS TO SUPPORT MARKET GROWTH 179
10.4 PRIMARY & SPECIAL STAINING 181
10.4.1 GROWING DEMAND FOR SPECIALIZED TISSUE & CELLULAR CHARACTERIZATION TO DRIVE GROWTH 181
10.5 DIGITAL PATHOLOGY 183
10.5.1 GROWING ADOPTION OF WHOLE-SLIDE IMAGING AND AI-ENABLED WORKFLOWS TO DRIVE GROWTH OF DIGITAL PATHOLOGY 183
11 ANATOMIC PATHOLOGY MARKET, BY DISEASE 186
11.1 INTRODUCTION 187
11.2 BREAST CANCER 188
11.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO FUEL MARKET 188
11.3 NON-SMALL-CELL LUNG CANCER 190
11.3.1 RISING CASES OF LUNG CANCER TO DRIVE ADOPTION 190
11.4 PROSTATE CANCER 191
11.4.1 GROWING RATE OF PROSTATE CANCER TO PROPEL MARKET 191
11.5 GASTRIC CANCER 193
11.5.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST MARKET 193
11.6 LYMPHOMA 195
11.6.1 RISING INCIDENCE OF NON-HODGKIN’S LYMPHOMA IN ADULTS
TO SUPPORT GROWTH 195
11.7 OTHER DISEASES 198
12 ANATOMIC PATHOLOGY MARKET VOLUME ANALYSIS,
BY DISEASE (NUMBER OF TESTS) 200
13 ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER 201
13.1 INTRODUCTION 202
13.2 HOSPITALS 202
13.2.1 RISING HEALTHCARE INVESTMENT TO CONTRIBUTE TO GROWTH 202
13.3 RESEARCH LABORATORIES 204
13.3.1 RISING DEMAND FOR SPECIALTY TESTS TO DRIVE MARKET 204
13.4 PHARMACEUTICAL COMPANIES 206
13.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET 206
13.5 CONTRACT RESEARCH ORGANIZATIONS 208
13.5.1 GROWING DEMAND FOR OUTSOURCING ANALYTICAL TESTING & CLINICAL TRIAL SERVICES TO BOOST MARKET 208
13.6 OTHER END USERS 210
14 ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE 213
14.1 INTRODUCTION 214
14.2 HISTOPATHOLOGY SERVICES 214
14.3 CYTOPATHOLOGY SERVICES 216
15 ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE 218
15.1 INTRODUCTION 219
15.2 IN-HOUSE 219
15.3 OUTSOURCED 221
16 ANATOMIC PATHOLOGY SERVICE MARKET, BY DISEASE 223
16.1 INTRODUCTION 224
16.2 BREAST CANCER 224
16.2.1 NON-SMALL CELL LUNG CANCER 226
16.2.2 PROSTATE CANCER 227
16.2.3 GASTRIC CANCER 229
16.2.4 LYMPOMA 230
16.2.5 OTHER DISEASE TYPE 232
17 ANATOMIC PATHOLOGY MARKET, BY REGION 234
17.1 INTRODUCTION 235
17.2 NORTH AMERICA 235
17.2.1 US 243
17.2.1.1 High healthcare expenditure to drive market 243
17.2.2 CANADA 250
17.2.2.1 Rising prevalence of cancer to fuel market 250
17.3 EUROPE 257
17.3.1 GERMANY 264
17.3.1.1 Favorable government initiatives to boost market 264
17.3.2 UK 271
17.3.2.1 Rising investments in cancer research to drive market 271
17.3.3 FRANCE 278
17.3.3.1 Increasing demand for cancer diagnostics to propel market 278
17.3.4 ITALY 285
17.3.4.1 High incidence of cancer and geriatric population to support growth 285
17.3.5 SPAIN 292
17.3.5.1 Increased cancer cases to boost market 292
17.3.6 REST OF EUROPE 299
17.4 ASIA PACIFIC 305
17.4.1 CHINA 313
17.4.1.1 Increasing focus on healthcare infrastructure to boost market 313
17.4.2 JAPAN 320
17.4.2.1 Established healthcare system to fuel market 320
17.4.3 INDIA 327
17.4.3.1 Presence of large patient pool and rapidly growing healthcare
sector to drive market 327
17.4.4 REST OF ASIA PACIFIC 334
17.5 LATIN AMERICA 341
17.5.1 GROWING ONCOLOGY PATIENT POOL, COMBINED WITH EXPANDING PUBLIC AND PRIVATE INVESTMENTS IN CANCER CARE, TO BOOST GROWTH 341
17.6 MIDDLE EAST & AFRICA 348
17.6.1 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO AID ANATOMIC PATHOLOGY MARKET 348
18 COMPETITIVE LANDSCAPE 356
18.1 INTRODUCTION 356
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 356
18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN ANATOMIC
PATHOLOGY MARKET 356
18.3 REVENUE ANALYSIS, 2023–2025 358
18.4 MARKET SHARE ANALYSIS, 2025 359
18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 359
18.4.2 US MARKET SHARE ANALYSIS, 2025 361
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 361
18.5.1 STARS 362
18.5.2 EMERGING LEADERS 362
18.5.3 PERVASIVE PLAYERS 362
18.5.4 PARTICIPANTS 362
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 364
18.5.5.1 Company footprint 364
18.5.5.2 Region footprint 364
18.5.5.3 Type footprint 365
18.5.5.4 Process footprint 365
18.5.5.5 End-user footprint 366
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 366
18.6.1 PROGRESSIVE COMPANIES 366
18.6.2 RESPONSIVE COMPANIES 366
18.6.3 DYNAMIC COMPANIES 367
18.6.4 STARTING BLOCKS 367
18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 368
18.6.5.1 Detailed list of key startups/SMEs 368
18.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 368
18.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 369
18.7 COMPANY VALUATION & FINANCIAL METRICS 369
18.7.1 FINANCIAL METRICS 369
18.7.2 COMPANY VALUATION 370
18.8 BRAND/PRODUCT COMPARISON 370
18.9 COMPETITIVE SCENARIO 371
18.9.1 PRODUCT LAUNCHES & APPROVALS 371
18.9.2 DEALS 372
18.9.3 EXPANSIONS 373
19 COMPANY PROFILES 374
19.1 KEY PLAYERS 374
19.1.1 F. HOFFMANN-LA ROCHE LTD. 374
19.1.1.1 Business overview 374
19.1.1.2 Products offered 375
19.1.1.3 Recent developments 377
19.1.1.3.1 Product launches & approvals 377
19.1.1.3.2 Deals 377
19.1.1.4 MnM view 378
19.1.1.4.1 Key strengths 378
19.1.1.4.2 Strategic choices 378
19.1.1.4.3 Weaknesses & competitive threats 378
19.1.2 DANAHER CORPORATION 379
19.1.2.1 Business overview 379
19.1.2.2 Products offered 380
19.1.2.3 Recent developments 382
19.1.2.3.1 Product launches & approvals 382
19.1.2.3.2 Deals 383
19.1.2.4 MnM view 384
19.1.2.4.1 Key strengths 384
19.1.2.4.2 Strategic choices 384
19.1.2.4.3 Weaknesses & competitive threats 384
19.1.3 PHC HOLDINGS CORPORATION (EPREDIA) 385
19.1.3.1 Business overview 385
19.1.3.2 Products offered 386
19.1.3.3 Recent developments 388
19.1.3.3.1 Product launches & approvals 388
19.1.3.3.2 Deals 388
19.1.3.4 MnM view 389
19.1.3.4.1 Key strengths 389
19.1.3.4.2 Strategic choices 389
19.1.3.4.3 Weaknesses & competitive threats 389
19.1.4 AGILENT TECHNOLOGIES, INC. 390
19.1.4.1 Business overview 390
19.1.4.2 Products offered 391
19.1.4.3 Recent developments 392
19.1.4.3.1 Product launches 392
19.1.4.3.2 Deals 393
19.1.4.4 MnM view 393
19.1.4.4.1 Key strengths 393
19.1.4.4.2 Strategic choices 393
19.1.4.4.3 Weaknesses & competitive threats 393
19.1.5 HOLOGIC INC. 394
19.1.5.1 Business overview 394
19.1.5.2 Products offered 395
19.1.5.3 Recent developments 396
19.1.5.3.1 Product approvals 396
19.1.5.4 MnM view 397
19.1.5.4.1 Key strengths 397
19.1.5.4.2 Strategic choices 397
19.1.5.4.3 Weaknesses & competitive threats 397
19.1.6 BECTON, DICKINSON AND COMPANY (BD) 398
19.1.6.1 Business overview 398
19.1.6.2 Products offered 399
19.1.6.3 Recent developments 401
19.1.6.3.1 Deals 401
19.1.6.3.2 Expansions 401
19.1.7 KONINKLIJKE PHILIPS N.V. 402
19.1.7.1 Business overview 402
19.1.7.2 Products offered 403
19.1.7.3 Recent developments 404
19.1.7.3.1 Deals 404
19.1.7.3.2 Expansions 405
19.1.8 MERCK KGAA 406
19.1.8.1 Business overview 406
19.1.8.2 Products offered 407
19.1.8.3 Recent developments 408
19.1.8.3.1 Expansions 408
19.1.9 SECTRA AB 409
19.1.9.1 Business overview 409
19.1.9.2 Products offered 410
19.1.9.3 Recent developments 411
19.1.9.3.1 Product approvals 411
19.1.9.3.2 Deals 411
19.1.9.3.3 Expansions 412
19.1.10 SAKURA FINETEK JAPAN CO., LTD. 413
19.1.10.1 Business overview 413
19.1.10.2 Products offered 413
19.1.10.3 Recent developments 415
19.1.10.3.1 Product launches 415
19.1.10.3.2 Deals 416
19.1.10.3.3 Expansions 416
19.2 OTHER PLAYERS 417
19.2.1 BIO SB 417
19.2.2 BIOGENEX 418
19.2.3 MILESTONE MEDICAL 419
19.2.4 HISTO-LINE LABORATORIES 420
19.2.5 DIAPATH S.P.A. 422
19.2.6 SLEE MEDICAL GMBH 423
19.2.7 AMOS SCIENTIFIC PTY LTD. 425
19.2.8 MEDITE MEDICAL GMBH 426
19.2.9 CELL SIGNALING TECHNOLOGY, INC. 427
19.2.10 CELLPATH LTD. 428
19.2.11 MICROS AUSTRIA 429
19.2.12 R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED 430
19.2.13 RWD LIFE SCIENCE CO., LTD. 431
19.2.14 MEDIMEAS 432
19.2.15 BRIGHT INSTRUMENTS 433
19.2.16 JINHUA YIDI MEDICAL APPLIANCE CO., LTD. 434
19.2.17 HAMAMATSU PHOTONICS K.K. 435
19.2.18 3DHISTECH LTD. 436
19.2.19 OPTRASCAN 437
19.2.20 DAKEWE 438
20 RESEARCH METHODOLOGY 439
20.1 RESEARCH DATA 439
20.1.1 SECONDARY DATA 440
20.1.1.1 List of secondary sources 440
20.1.1.2 Key data from secondary sources 441
20.1.2 PRIMARY DATA 441
20.1.2.1 Breakdown of primary interviews 443
20.2 MARKET SIZE ESTIMATION 444
20.2.1 TOTAL MARKET SIZE: ANATOMIC PATHOLOGY MARKET 444
20.2.2 BOTTOM-UP APPROACH 444
20.2.2.1 Approach 2: Study of annual reports and investor presentations 445
20.2.2.2 Approach 3: Primary interviews 445
20.2.2.3 Growth forecast 445
20.2.3 TOP-DOWN APPROACH 446
20.3 DATA TRIANGULATION 446
20.4 RESEARCH ASSUMPTIONS 447
20.4.1 STUDY-RELATED ASSUMPTIONS 447
20.5 STUDY ASSUMPTIONS 447
20.5.1 PARAMETRIC ASSUMPTIONS 448
20.5.2 GROWTH RATE ASSUMPTIONS 448
20.6 RESEARCH LIMITATIONS 449
20.7 RISK ASSESSMENT 449
21 APPENDIX 450
21.1 DISCUSSION GUIDE 450
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 454
21.3 CUSTOMIZATION OPTIONS 456
21.4 RELATED REPORTS 456
21.5 AUTHOR DETAILS 457

ページTOPに戻る

List of Tables/Graphs

TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2024 VS. 2030 VS. 2040 (MILLION) 58.
TABLE 2 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2024 VS. 2030 VS. 2040 (MILLION) 58.
TABLE 3 % OF PERSONALIZED MEDICINES IN OVERALL DRUG APPROVAL BY FDA, 2015–2024 61.
TABLE 4 ANATOMIC PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 70.
TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 71.
TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS 72.
TABLE 7 EUROPE: MACROECONOMIC INDICATORS 73.
TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS 73.
TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS 73.
TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 73.
TABLE 11 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 78.
TABLE 12 AVERAGE SELLING PRICE OF ANATOMIC PATHOLOGY PRODUCTS, BY REGION, 2024–2026 (USD) 79.
TABLE 13 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 80.
TABLE 14 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 81.
TABLE 15 ANATOMIC PATHOLOGY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 81.
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 85.
TABLE 17 KEY PATENTS IN ANATOMIC PATHOLOGY MARKET, 2022–2026 93.
TABLE 18 KEY COMPANIES IMPLEMENTING AI IN ANATOMIC PATHOLOGY MARKET 96.
TABLE 19 CLASSIFICATION OF IVD DEVICES IN EUROPE 98.
TABLE 20 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 99.
TABLE 21 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101.
TABLE 22 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101.
TABLE 23 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102.
TABLE 24 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102.
TABLE 25 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102.
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 107.
TABLE 27 KEY BUYING CRITERIA, BY END USER 107.
TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 108.
TABLE 29 ANATOMIC PATHOLOGY MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 109.
TABLE 30 ANATOMIC PATHOLOGY PRODUCT MARKET, BY TYPE, 2024–2031 (USD MILLION) 113.
TABLE 31 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 113.
TABLE 32 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 114.
TABLE 33 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 115.
TABLE 34 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 115.
TABLE 35 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 115.
TABLE 36 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 37 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 116.
TABLE 38 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 117.
TABLE 39 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 40 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 41 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 42 PRIMARY HISTOPATHOLOGY ANTIBODIES AVAILABLE IN MARKET 118.
TABLE 43 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY HISTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 119.
TABLE 44 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 45 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 46 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 120.
TABLE 47 ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY HISTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 120.
TABLE 48 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 49 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 50 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY HISTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 51 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 122.
TABLE 52 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 122.
TABLE 53 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 123.
TABLE 54 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 123.
TABLE 55 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 123.
TABLE 56 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY STAINS & SOLVENTS, BY REGION, 2024–2031 (USD MILLION) 124.
TABLE 57 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 124.
TABLE 58 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 59 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 60 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY FIXATIVES, BY REGION, 2024–2031 (USD MILLION) 126.
TABLE 61 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 62 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 63 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 64 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 127.
TABLE 65 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 66 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 67 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 68 HISTOPATHOLOGY PROBES AVAILABLE IN MARKET 129.
TABLE 69 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY PROBES, BY REGION, 2024–2031 (USD MILLION) 130.
TABLE 70 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 71 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 130.
TABLE 72 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HISTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 131.
TABLE 73 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 131.
TABLE 74 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 75 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 76 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER HISTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 77 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY TYPE, 2024–2031 (USD MILLION) 133.
TABLE 78 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 79 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 80 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 81 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 82 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY TYPE, 2024–2031 (USD MILLION) 135.
TABLE 83 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 136.
TABLE 84 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 85 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 86 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 87 PRIMARY CYTOPATHOLOGY ANTIBODIES AVAILABLE IN MARKET 137.
TABLE 88 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY CYTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 138.
TABLE 89 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 90 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 91 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 92 ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY CYTOPATHOLOGY ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 93 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 94 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 95 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SECONDARY CYTOPATHOLOGY ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 96 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 141.
TABLE 97 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 141.
TABLE 98 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 99 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 100 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 101 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY STAINS & SOLVENTS, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 102 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 103 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 104 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY STAINS & SOLVENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 105 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY FIXATIVES, BY REGION, 2024–2031 (USD MILLION) 145.
TABLE 106 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 107 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 108 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY FIXATIVES, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 109 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 146.
TABLE 110 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 111 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 112 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 113 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY PROBES, BY REGION, 2024–2031 (USD MILLION) 148.
TABLE 114 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 115 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 116 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CYTOPATHOLOGY PROBES, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 117 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 150.
TABLE 118 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 119 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 120 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER CYTOPATHOLOGY CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 121 ANATOMIC PATHOLOGY PRODUCT MARKET FOR INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION) 152.
TABLE 122 KEY SLIDE STAINING SYSTEMS AVAILABLE IN MARKET 152.
TABLE 123 ANATOMIC PATHOLOGY PRODUCT MARKET FOR SLIDE STAINING SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 153.
TABLE 124 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SLIDE STAINING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 125 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SLIDE STAINING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 126 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR SLIDE STAINING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 127 KEY TISSUE PROCESSING SYSTEMS AVAILABLE IN MARKET 155.
TABLE 128 ANATOMIC PATHOLOGY PRODUCT MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 155.
TABLE 129 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 130 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 131 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 132 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CELL PROCESSORS, BY REGION, 2024–2031 (USD MILLION) 157.
TABLE 133 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CELL PROCESSORS, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 134 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CELL PROCESSORS, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 135 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CELL PROCESSORS, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 136 MICROTOMES AVAILABLE IN MARKET 159.
TABLE 137 ANATOMIC PATHOLOGY PRODUCT MARKET FOR MICROTOMES, BY REGION, 2024–2031 (USD MILLION) 159.
TABLE 138 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR MICROTOMES, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 139 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR MICROTOMES, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 140 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR MICROTOMES, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 141 ANATOMIC PATHOLOGY PRODUCT MARKET FOR EMBEDDING SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 161.
TABLE 142 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR EMBEDDING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 161.
TABLE 143 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR EMBEDDING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 144 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR EMBEDDING SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 145 ANATOMIC PATHOLOGY PRODUCT MARKET FOR COVERSLIPPERS, BY REGION, 2024–2031 (USD MILLION) 163.
TABLE 146 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR COVERSLIPPERS, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 147 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR COVERSLIPPERS, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 148 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR COVERSLIPPERS, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 149 DIGITAL PATHOLOGY SCANNERS AVAILABLE IN MARKET 165.
TABLE 150 ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY REGION, 2024–2031 (USD MILLION) 165.
TABLE 151 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 152 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 153 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 154 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 167.
TABLE 155 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 156 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 157 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 158 SOFTWARE AVAILABLE IN MARKET 169.
TABLE 159 ANATOMIC PATHOLOGY PRODUCT MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 169.
TABLE 160 ANATOMIC PATHOLOGY PRODUCT MARKET FOR AI-INTEGRATED SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 170.
TABLE 161 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 162 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 163 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 164 ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-AI-INTEGRATED SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 172.
TABLE 165 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 166 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 167 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-AI-INTEGRATED SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 168 ANATOMIC PATHOLOGY PRODUCT MARKET FOR STORAGE SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 174.
TABLE 169 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 170 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 171 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 172 ANATOMIC PATHOLOGY PRODUCT MARKET, BY PROCESS, 2024–2031 (USD MILLION) 177.
TABLE 173 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PREANALYTICS/SAMPLE PREPARATION, BY REGION, 2024–2031 (USD MILLION) 178.
TABLE 174 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PREANALYTICS/SAMPLE PREPARATION, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 175 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PREANALYTICS/SAMPLE PREPARATION, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 176 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PREANALYTICS/SAMPLE PREPARATION, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 177 ANATOMIC PATHOLOGY PRODUCT MARKET FOR ADVANCED STAINING/IHC, BY REGION, 2024–2031 (USD MILLION) 180.
TABLE 178 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR ADVANCED STAINING/IHC, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 179 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR ADVANCED STAINING/IHC, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 180 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR ADVANCED STAINING/IHC, BY COUNTRY, 2024–2031 (USD MILLION) 181.
TABLE 181 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY & SPECIAL STAINING, BY REGION, 2024–2031 (USD MILLION) 182.
TABLE 182 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY & SPECIAL STAINING, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 183 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY & SPECIAL STAINING, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 184 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PRIMARY & SPECIAL STAINING, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 185 ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY, BY REGION, 2024–2031 (USD MILLION) 184.
TABLE 186 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 187 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 188 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 189 GLOBAL CANCER INCIDENCE, 2022 VS. 2040 187.
TABLE 190 ANATOMIC PATHOLOGY PRODUCT MARKET, BY DISEASE, 2024–2031 (USD MILLION) 187.
TABLE 191 BREAST CANCER INCIDENCE, BY REGION, 2024 VS. 2050 188.
TABLE 192 ANATOMIC PATHOLOGY PRODUCT MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 188.
TABLE 193 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 194 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 195 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 196 ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-SMALL-CELL LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 190.
TABLE 197 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-SMALL-CELL LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 198 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-SMALL-CELL LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 199 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR NON-SMALL-CELL LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 200 PROSTATE CANCER INCIDENCE, BY REGION, 2024 VS. 2050 192.
TABLE 201 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 192.
TABLE 202 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 203 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 204 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 205 ANATOMIC PATHOLOGY PRODUCT MARKET FOR GASTRIC CANCER, BY, BY REGION, 2024–2031 (USD MILLION) 194.
TABLE 206 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR GASTRIC CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 207 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR GASTRIC CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 208 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR GASTRIC CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 209 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2024 VS. 2050 196.
TABLE 210 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2024 VS. 2050 196.
TABLE 211 ANATOMIC PATHOLOGY PRODUCT MARKET FOR LYMPHOMA, BY REGION, 2024–2031 (USD MILLION) 196.
TABLE 212 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 213 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 214 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 215 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION) 198.
TABLE 216 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 217 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 218 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 219 ANATOMIC PATHOLOGY MARKET, BY DISEASE, 2024–2031 (NO. OF TESTS) 200.
TABLE 220 ANATOMIC PATHOLOGY PRODUCT MARKET, BY END USER, 2024–2031 (USD MILLION) 202.
TABLE 221 ANATOMIC PATHOLOGY PRODUCT MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION) 203.
TABLE 222 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 223 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 224 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 225 ANATOMIC PATHOLOGY PRODUCT MARKET FOR RESEARCH LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 205.
TABLE 226 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 227 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 228 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 229 ANATOMIC PATHOLOGY PRODUCT MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 207.
TABLE 230 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 231 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 232 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 233 ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 209.
TABLE 234 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 235 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 236 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 237 ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 211.
TABLE 238 NORTH AMERICA: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 239 EUROPE: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 240 ASIA PACIFIC: ANATOMIC PATHOLOGY PRODUCT MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 241 ANATOMIC PATHOLOGY SERVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 214.
TABLE 242 ANATOMIC PATHOLOGY SERVICE MARKET FOR HISTOPATHOLOGY SERVICES, BY REGION, 2024–2031 (USD MILLION) 214.
TABLE 243 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR HISTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 214.
TABLE 244 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR HISTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 245 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICES MARKET FOR HISTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 246 ANATOMIC PATHOLOGY SERVICE MARKET FOR CYTOPATHOLOGY SERVICES, BY REGION, 2024–2031 (USD MILLION) 216.
TABLE 247 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR CYTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 248 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR CYTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 249 ASIA PACIFIC: ANATOMIC PATHOLOGY SERVICE MARKET FOR CYTOPATHOLOGY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 250 ANATOMIC PATHOLOGY SERVICE MARKET, BY MODEL, 2024–2031 (USD MILLION) 219.
TABLE 251 ANATOMIC PATHOLOGY SERVICE MARKET FOR IN-HOUSE, BY REGION, 2024–2031 (USD MILLION) 219.
TABLE 252 NORTH AMERICA: ANATOMIC PATHOLOGY SERVICE MARKET FOR IN-HOUSE, BY COUNTRY, 2024–2031 (USD MILLION) 219.
TABLE 253 EUROPE: ANATOMIC PATHOLOGY SERVICE MARKET FOR IN-HOUSE, BY COUNTRY, 2024–2031 (USD MILLION) 220.
FIGURE 1 ANATOMIC PATHOLOGY MARKET SEGMENTATION & REGIONAL SCOPE 45.
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 49.
FIGURE 3 GLOBAL ANATOMIC PATHOLOGY MARKET, 2024–2031 49.
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ANATOMIC PATHOLOGY MARKET, 2023–2025 50.
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF ANATOMIC PATHOLOGY MARKET 51.
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN ANATOMIC PATHOLOGY MARKET, 2025 52.
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53.
FIGURE 8 RISING CASES OF CANCER TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 54.
FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 54.
FIGURE 10 PREANALYTICS/SAMPLE PREPARATION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 55.
FIGURE 11 BREAST CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 55.
FIGURE 12 HOSPITALS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 56.
FIGURE 13 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 56.
FIGURE 14 ANATOMIC PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57.
FIGURE 15 ANATOMIC PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 69.
FIGURE 16 ANATOMIC PATHOLOGY MARKET: SUPPLY CHAIN ANALYSIS 74.
FIGURE 17 ANATOMIC PATHOLOGY MARKET: VALUE CHAIN ANALYSIS 75.
FIGURE 18 ANATOMIC PATHOLOGY MARKET: ECOSYSTEM ANALYSIS 76.
FIGURE 19 ANATOMIC PATHOLOGY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 82.
FIGURE 20 NUMBER OF DEALS & FUNDING ACTIVITIES IN ANATOMIC PATHOLOGY MARKET 83.
FIGURE 21 PATENT ANALYSIS FOR ANATOMIC PATHOLOGY, JANUARY 2016–DECEMBER 2025 93.
FIGURE 22 MARKET POTENTIAL OF AI IN ANATOMIC PATHOLOGY MARKET 95.
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 106.
FIGURE 24 KEY BUYING CRITERIA, BY END USER 107.
FIGURE 25 NORTH AMERICA: ANATOMIC PATHOLOGY MARKET SNAPSHOT 236.
FIGURE 26 ASIA PACIFIC: ANATOMIC PATHOLOGY MARKET SNAPSHOT 306.
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN ANATOMIC PATHOLOGY MARKET, 2023–2025 (USD MILLION) 358.
FIGURE 28 ANATOMIC PATHOLOGY MARKET SHARE ANALYSIS, 2025 (GLOBAL) 359.
FIGURE 29 ANATOMIC PATHOLOGY MARKET SHARE ANALYSIS, 2025 (US) 361.
FIGURE 30 ANATOMIC PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 363.
FIGURE 31 ANATOMIC PATHOLOGY MARKET: COMPANY FOOTPRINT 364.
FIGURE 32 ANATOMIC PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 367.
FIGURE 33 EV/EBITDA OF KEY VENDORS 369.
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 370.
FIGURE 35 ANATOMIC PATHOLOGY MARKET: BRAND/PRODUCT COMPARISON FOR ANATOMIC PATHOLOGY 370.
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 375.
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 380.
FIGURE 38 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025) 386.
FIGURE 39 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 391.
FIGURE 40 HOLOGIC INC.: COMPANY SNAPSHOT (2025) 395.
FIGURE 41 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025) 399.
FIGURE 42 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2025) 403.
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 407.
FIGURE 44 SECTRA AB: COMPANY SNAPSHOT (2025) 410.
FIGURE 45 RESEARCH DESIGN 439.
FIGURE 46 LIST OF PRIMARY SOURCES 442.
FIGURE 47 KEY INDUSTRY INSIGHTS 443.
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 443.
FIGURE 49 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS 444.
FIGURE 50 CAGR PROJECTIONS 445.
FIGURE 51 TOP-DOWN APPROACH 446.
FIGURE 52 DATA TRIANGULATION 447.